Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Minerva Cardioangiol. 2012 Dec;60(6):611-28.

Dual antiplatelet therapy for primary and secondary prevention.

Author information

  • 1Department of Medicine, University Hospital and New Jersey Medical School, Newark, NJ, USA.

Abstract

The concomitant use of aspirin and an ADP receptor (P2Y12) blocker, also known as dual antiplatelet therapy (DAPT), has been extensively investigated as a primary and secondary prevention strategy in an effort to reduce the risk of cardiovascular events. In this manuscript the authors review the current guideline recommendations for DAPT and discuss the scientific data that supports these recommendations. Reported are also the scientific knowledge gaps and how future studies are likely to delineate these issues. Incremental knowledge is not likely to be an alternative to individualized care provided by the astute clinician to his patient. In consideration for prescribing DAPT (drug, dosage and duration) the clinician will have to weigh the potential benefits (reduction in death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke) and risks (severe or life-threatening bleeding) for each and every patient.

PMID:
23147438
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Minerva Medica
    Loading ...
    Write to the Help Desk